Human Bone Graft for Fixation of Osteochondral Defects in the Knee Joint

Sponsor
Medical University of Vienna (Other)
Overall Status
Recruiting
CT.gov ID
NCT03777735
Collaborator
Surgebright Gmbh (Industry)
20
5
71.3
4
0.1

Study Details

Study Description

Brief Summary

This observational study is to document the application of a human bone graft in the surgical repair of bone fragment detachment in the knee joint (osteochondral defect) and its subsequent healing process.

Condition or Disease Intervention/Treatment Phase
  • Procedure: human bone graft screw

Detailed Description

For the treatment of bone fractures metal screws have been used for decades. Removal of material is the major disadvantage of conventional osteosynthesis and requires a second intervention, with all the complications and risks for each patient. In order to avoid this second surgery, it is possible to use human bone screw grafts instead of metal screws.

The bone graft helps to create a solid, bony connection. This connection leads to an extension, a bone remodeling, bone installation and optimal reparation process in the affected area.

The comparatively rare occurrence of suitable patients contributes to the fact that there has not been enough systematic research to objectively confirm the benefits of the product, which is why this observational study is being conducted.

In total, 20 patients will be enrolled in several centers in Austria. The low number of cases and the multicenter design is due to the rarity of suitable patients.

This observational study will use Shark Screw® grafts without exception at all participating centers. These grafts are manufactured by two tissue banks, the Austrian Tissue Bank surgebright and the German Institute for Cell and Tissue Replacement (DZIG) and were approved by the competent Austrian authority (AGES) in 2016.

All patients participating in this observational study, due to a medical indication, undergo surgical treatment of osteochondral defects using the bone screws mentioned above.

Postoperatively, the patients are observed over a period of 24 months. In total, there are five follow-up examinations during which clinical examinations, x-rays and a magnetic resonance tomography (MRI) is performed. In addition the KOS-ADL and IKDC Score are collected.

Study Design

Study Type:
Observational
Anticipated Enrollment :
20 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Multicentric Observational Study on the Use of a Human Bone Graft in Osteochondral Defects
Actual Study Start Date :
Apr 24, 2018
Anticipated Primary Completion Date :
Apr 1, 2023
Anticipated Study Completion Date :
Apr 1, 2024

Arms and Interventions

Arm Intervention/Treatment
human bone graft screw

The patients will receive human bone graft screws surgically.

Procedure: human bone graft screw
All patients undergo surgical treatment of osteochondral defects in the knee joint with human bone graft screws.

Outcome Measures

Primary Outcome Measures

  1. incidence of surgical revisions [1 year]

    Was a surgical revision done postoperatively? YES/NO

  2. incidence of loosening of the screw [1 year]

    based on x-rays or MRI: Is a loosening of the screw visible? YES/NO

  3. incidence of cracking of the screw [1 year]

    based on x-rays or MRI: Is a cracking of the screw visible? YES/NO

  4. incidence of loosening of the osteochondral fragment [1 year]

    based on x-rays or MRI: Is a loosening of the osteochondral fragment visible? YES/NO

  5. incidence of cracking of the osteochondral fragment [1 year]

    based on x-rays or MRI: Is a cracking of the osteochondral fragment visible? YES/NO

  6. time to healing of the osteochondral fragment [1 year]

    based on x-rays or MRI: Has the osteochondral fragment healed into the surrounding area? YES/NO

  7. incidence of postoperative pseudoarthrosis [1 year]

    based on x-rays or MRI: Is a postoperative pseudoarthrosis visible? YES/NO

  8. evaluation postoperative pain (VAS) [1 year]

    The visual analogue scale (VAS) is a vertical line, 10 centimeters (100 mm) in length, anchored by 2 verbal descriptors, one for each symptom extremes (0mm = no pain - 100mm = worst imaginable pain). A higher score indicates more pain.

  9. duration of postoperative job-related incapacity [1 year]

    evaluation of duration

Secondary Outcome Measures

  1. patient satisfaction (VAS) [1 year]

    The visual analogue scale (VAS) is a vertical line, 10 centimeters (100 mm) in length, anchored by 2 verbal descriptors, one for each symptom extremes (0mm = very satisfied - 100mm = not satisfied at all). A higher score indicates less satisfaction.

  2. Knee Outcome Survey - Activities of Daily Living Scale (KOS-ADL) [1 year]

    The KOS ADL score includes 14 questions and is divided in 2 subscales, symptoms (6 items, max. score 30) and functional restrictions (8 items, max. score 40). The scores of the answers range from 0 to 5 points. 0 points mean no impairment of everyday activities, while 5 points represent the greatest possible impairment. All points are summed up. From this, the KOS-ADL score is calculated as the proportion of the total response points from the possible maximum score (70) in percent. KOS ADL Score [%] = ( symptoms pts. + functional restrictions pts.)*100/70. The percentage ranges from 0-100%. 0% means no impairment, while 100% represents the greatest possible impairment.

  3. International Knee Documentation Committee Subjective Knee Form (IKDC Score) [1 year]

    The IKDC Score contains 19 questions (7 questions for symptomatology, 10 concerning function, 2 about sport activity). The lowest function level or the highest symptom level receives the score value 1. The highest function level or the lowest symptom level is given the number n according to the number n of possible answers. With the exception of question 10 "Functioning before knee injury", the remaining 18 response points are summed up. This gives the "raw sum". The lowest possible score is 18 and the maximum possible score is 87. The raw sum is converted into a scale of 0 to 100 using the following formula: ((raw score - lowest possible score)/score range)*100. 0 points mean the greatest possible impairment, while 100 points mean complete freedom from symptoms and functioning. The IKDC score can only be calculated if at least 16 of the 18 questions have been answered.

Eligibility Criteria

Criteria

Ages Eligible for Study:
8 Years to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Indication for the use of a human bone graft in the surgical treatment of osteochondral defects

  • legal capability of adults, guardians and adolescents aged 14 to 17 years, age-appropriate perceptivity for children 8 to 13 years old

  • Written consent to participation in the study after previous written and oral education (additional consent for participation of minors in the study after prior written and oral education by at least one parent)

  • Age ≥ 8 years

Exclusion Criteria:
  • Insufficient knowledge of the German language

  • Alcohol and drug abuse

  • Pregnant or breastfeeding woman

  • Foreseeable compliance issues

  • Neoplastic diseases, malignant bone tumors, rheumatoid arthritis

  • Active osteomyelitis

  • Ulcerations in the area of the skin of the surgical area

  • Immunosuppressive drugs that can not be discontinued

Contacts and Locations

Locations

Site City State Country Postal Code
1 LKH-Univ.Klinikum Graz Graz Austria 8036
2 Barmherzige Schwestern Hospital Ried Ried Im Innkreis Austria 4910
3 General Hospital Vienna Vienna Austria 1090
4 Orthopedic Center Otto-Wagner-Spital Vienna Austria 1140
5 Hospital Wels- Grieskirchen Wels Austria 4600

Sponsors and Collaborators

  • Medical University of Vienna
  • Surgebright Gmbh

Investigators

  • Principal Investigator: Catharina Chiari, MD, Medical University Vienna

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Catharina Chiari, Univ. Prof. Dr. Catharina Chiari, MSc, Medical University of Vienna
ClinicalTrials.gov Identifier:
NCT03777735
Other Study ID Numbers:
  • OD1
First Posted:
Dec 17, 2018
Last Update Posted:
Aug 24, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Catharina Chiari, Univ. Prof. Dr. Catharina Chiari, MSc, Medical University of Vienna
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 24, 2022